Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensiv...
Will this new test give Labcorp a competitive edge over rivals in the neurology diagnostics market and how might it impact its market share?
What is the expected adoption rate for the Lumipulse pTau‑217/Beta Amyloid 42 Ratio test versus existing Alzheimer’s diagnostics?
How will the launch of the FDA‑cleared blood test affect Labcorp’s revenue forecasts and earnings guidance?
6 days ago